Increased Risk of Cardiovascular Death with Febuxostat

Like Comment

The FDA recently added a new boxed warning to the prescribing information for febuxostat based on results from the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial.  This trial was required by the FDA and was a  randomized, double-blind trial comparing febuxostat to allopurinal in 6190 people with gout.  The primary endpoint was a composite of major adverse cardiovascular events including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and unstable angina with urgent revascularization. While the agents were equivalent for the composite primary endpoint, there were significantly more cardiovascular deaths and deaths due to all cause mortality in the patients treated with febuxostat.  In addition to the Black Box Warning, the FDA is now restricting the use of febuxostat to patients that failed or intolerant of allopurinol.  


Click here to read more about the FDA ruling FDA press release

Read more about allopurinol and febuxostat in  Top 300 Pharmacy Drug Cards.  If you or your institution subscribes to AccessPharmacy, use or create your MyAccess Profile to sign-in to the Flash Card section.  If your institution does not provide access, ask your medical librarian about subscribing.

For a chance to win GREAT prizes and learn more about medications in the Top 300, check out the Drug Card Scavenger Hunt page on AccessPharmacy. Follow us to receive email alerts when new Drug of the Week and Drug Card Scavenger Hunt updates are posted.

Jill Kolesar & Lee Vermeulen

Professors, University of Kentucky